argenx (Belgian) sells Vyvgart for autoimmune diseases.
argenx SE (ARGX) is expected to report earnings on Thursday, October 22, 2026, before the open. Estimated release time before open. Consensus EPS estimate is $7.44.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-23 | Jun 2026 qtr | $6.27 | $7.32 | +16.7% | $2.82B |
| 2026-05-07 | Mar 2026 qtr | $4.75 | $12.25 | — | $2.07B |
| 2026-02-26 | Dec 2025 qtr | $6.24 | $8.02 | +28.5% | $3.21B |
| 2025-10-30 | Sep 2025 qtr | $4.16 | $5.18 | — | $1.13B |
| 2025-03-31 | Mar 2025 qtr | $2.89 | $2.78 | -3.8% | $790.68M |
| 2024-09-30 | Jun 2024 qtr | $-1.07 | $1.52 | — | $573.24M |
| 2024-06-30 | Mar 2024 qtr | $-0.80 | $-0.55 | — | $901.94M |
| 2024-03-31 | Dec 2023 qtr | $-1.70 | $-1.04 | — | $401.00M |
ARGX has beaten consensus EPS in 2 of its last 3 scored quarters.
See ARGX on the live calendar →